ASX Market Report
|All Ordinaries||5901||15||0.26||$A vs $US||0.7565||0.0010||0.13|
|S&P/ASX 200||5872||18||0.30||$A vs GBP||0.5914||0.0023||0.39|
|10-year Bond Rate||2.63||--||--||$A vs YEN||83.29||0.20||0.24|
|$A vs EUR||0.6976||0.0027||0.38|
|$A vs $NZ||1.0763||0.0034||0.32|
To view this information
become a Premium Member
|ASX Code||Company Name||Impact||Recommendation|
|CCL||Coca-Cola Amatil Limited (CCL)|
|DUE||DUET Group (DUE)|
|HGG||Henderson Group PLC (HGG)|
|TWR||Tower Limited (TWR)|
|ILU||Iluka Resources Limited (ILU)|
|STO||Santos Limited (STO)|
|WPL||Woodside Petroleum Limited (WPL)|
Monday 24 April - The Australia market started the week on a high point, with broad based gains across most sectors. It proved a volatile trading day as the ASX 200 index pared early gains after hitting its intraday high, slid into the black in late afternoon, but bounced back with moderate gains before the closing bell. Most sectors posted positive results for this session, with only materials and telecommunication services closing lower. The Australian dollar appreciated against most major currencies.
The All Ordinaries added 15.10 points (0.26%) to 5,900.70 while the S&P/ASX 200 rose 17.70 points (0.30%) to 5,871.80.
Village Roadshow Limited (VRL)
Village Roadshow announced a trading update for Village Roadshow Theme Parks (VRTP). Following its half year results announcement in February 2017, the Theme Parks division continued to be impacted by the tragedy which occurred at Dreamworld in October 2016, and was further affected by cyclonic weather conditions in March/April 2017. During the peak summer period, the performance of the Gold Coast parks was cushioned by strength in international and interstate visitation. Attendance by the core local market has remained weak since the tragedy, with the impact more pronounced outside peak summer trading. For the nine months to 31 March 2017, total attendance for the Gold Coast parks is down 9.4%1. Additionally, in the month of March 2017, membership renewals also declined. VRL fell 26 cents (-6.48%) to $3.75.
Sirtex Medical Limited (SRX)
Sirtex Medical announced the results of the 459 patient SARAH clinical study comparing SIR-Spheres Y-90 resin microspheres versus the current standard-of-care systemic therapy sorafenib in patients with non-resectable advanced hepatocellular carcinoma (HCC), the most common type of primary liver cancer. While the study did not meet the primary endpoint of OS superiority versus sorafenib in the ITT analysis, it showed both treatments resulted in a similar OS in patients with beneficial safety, toxicity and Quality of Life (QoL) favouring SIR-Spheres microspheres. SRX plunged $2.20 (-12.94%) to $14.80.
The NZX 50 gained 25.72 points (0.36%) to 7,222.94 while the Nikkei lifted 255.13 points (1.37%) to close at 18,875.88.
The Australian dollar was last quoted at 75.65 US cents.
Companies commencing Ex-Dividend Trading Today (ASX 300):
Ridley Corporation Limited
© 2017 Morningstar. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO").